Sanofi: Q1 EPS down 82%
(CercleFinance.com) - Sanofi has published Q1 2018 IFRS EPS of 0.
81 euro, down 82%, due to the capital gain from the sale of its animal health division in 2017.
At 1.28 euro, EPS of the group's businesses increased by 1.4% at constant exchanges rates.
Revenues reached 7,898 million euros, down 8.7% as reported, down 0.4% at constant exchange rates and down 1.1% in organic terms, with the strong performance of Speciality Medicines offset by the loss of exclusivity of Lantus and sevelamer in the United States.
Sanofi still expects 2018 EPS growth of between +2% and +5% at constant currencies, unless there are any major adverse unexpected events. The pharmaceutical group has announced a 1.5 billion euro share repurchase program that is expected to be completed in mid-2019.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
81 euro, down 82%, due to the capital gain from the sale of its animal health division in 2017.
At 1.28 euro, EPS of the group's businesses increased by 1.4% at constant exchanges rates.
Revenues reached 7,898 million euros, down 8.7% as reported, down 0.4% at constant exchange rates and down 1.1% in organic terms, with the strong performance of Speciality Medicines offset by the loss of exclusivity of Lantus and sevelamer in the United States.
Sanofi still expects 2018 EPS growth of between +2% and +5% at constant currencies, unless there are any major adverse unexpected events. The pharmaceutical group has announced a 1.5 billion euro share repurchase program that is expected to be completed in mid-2019.
Copyright (c) 2018 CercleFinance.com. All rights reserved.